Yuta Baba

Yuta Baba

Auto-generated profile, based on publicly available information

Yuta Baba

Division of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
NHNorimichi Hattori
Norimichi Hattori
YKYukiko Kawaguchi
Yukiko Kawaguchi
YSYohei Sasaki
Yohei Sasaki
SSShotaro Shimada
Shotaro Shimada
SMSo Murai
So Murai
TNTsuyoshi Nakamaki
Tsuyoshi Nakamaki
After allogeneic stem cell transplantation (alloSCT), several immune checkpoints play an important role in the antileukemic immune response in the bone marrow (BM) microenvironment. However, immune checkpoint expression levels in the BM have not been reported after alloSCT in patients with acute myeloid leukemia (AML). We investigated the clinical impact of immune checkpoint expression in BM samples after alloSCT for AML. Higher expression of T cell immunoreceptor with Ig and ITIM domains (TIGIT) was associated with a decreased incidence of acute graft-versus-host disease (P = .048) and poor overall (P = .046) and progression-free survival (P = 0.024). In addition, higher expression of TIGIT at engraftment after alloSCT was correlated with a decreased number of natural killer cells in BM (P = .019). Monitoring TIGIT expression in the BM could be useful for predicting outcome after alloSCT for AML. Our findings raise the possibility that blockade of TIGIT would improve survival.

1 September 2018 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
NHNorimichi Hattori
Norimichi Hattori
BSBungo Saito
Bungo Saito
YSYohei Sasaki
Yohei Sasaki
SSShotaro Shimada
Shotaro Shimada
SMSo Murai
So Murai
TNTsuyoshi Nakamaki
Tsuyoshi Nakamaki
Rapid immune recovery following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is important for clinical outcome prediction. In most studies, immune recovery after allo-HSCT is monitored via peripheral blood. However, few reports regarding the status of absolute lymphocyte subsets in the bone marrow (BM) microenvironment have been undertaken. Therefore, we evaluated the clinical impact of immune recovery in the early period following allo-HSCT using BM samples. We showed that delayed natural killer cell recovery was independently associated with a poor prognosis for overall survival (hazard ratio [HR], 3.07; 95% confidence interval [CI], 1.37- 6.89; P = .007), progression-free survival (HR, 3.42; 95% CI, 1.47-7.94; P = .004), and nonrelapse mortality (HR, 6.68; 95% CI, 1.82-25.0; P = .004) by multivariate analysis. In addition, low NK cell counts were associated with the presence of 1 or more bacterial, viral, or fungal infections. Our results indicate that investigating absolute lymphocyte subsets in BM in the early phase following allo-HSCT can be useful for predicting and improving survival outcomes.

7 March 2019 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
NANana Arai
Nana Arai
MHMayumi Homma
Mayumi Homma
MAMaasa Abe
Maasa Abe
YBYuta Baba
Yuta Baba
SMSo Murai
So Murai
MTMasafumi Takimoto
Masafumi Takimoto

1 April 2018 in Leukemia Research
Verified
Journal Article
Open access
YBYuta Baba
Yuta Baba
BSBungo Saito
Bungo Saito
SSShotaro Shimada
Shotaro Shimada
YSYohei Sasaki
Yohei Sasaki
SMSo Murai
So Murai
TNTsuyoshi Nakamaki
Tsuyoshi Nakamaki
Studies showed red cell distribution width (RDW) can improve the detection of morphological changes in red blood cells and the understanding of their contribution to dyserythropoiesis in myelodysplastic syndrome (MDS). The purpose of the study was to evaluate dyserythropoiesis in MDS by RDW analysis and to explore the utility of RDW in clinical practice. We retrospectively analyzed laboratory and clinical data of 101 patients (59 patients was refractory anemia (RA) according to the French-American-British (FAB) classification). In patients with RA, RDW was showed weak inverse correlation with both hemoglobin concentration (Hb) (rs = -0.37, P = 0.0035) and mean corpuscular hemoglobin concentration (MCHC) (rs = -0.36, P = 0.0047). On the other hand, RDW was showed weak correlation with the number of ringed sideroblasts in bone marrow (rs = 0.31, P = 0.023). The increased RDW (≥15.0%) was associated with shorter overall survival (OS) (P = 0.0086). In patients with refractory anemia with excess blasts (RAEB) and RAEB in transformation (RAEB-t), effect of RDW on OS was less evident. These results suggested that increased RDW might reflect dyserythropoiesis, associated with deregulated hemoglobin synthesis and iron metabolism in MDS. Furthermore, increased RDW may have potential to be a prognostic significance in RA.

16 May 2025 in Gut Microbes
Verified
Journal Article
Open access
YBYuta Baba
Yuta Baba
KTKohei Tajima
Kohei Tajima
KYKiyoshi Yoshimura
Kiyoshi Yoshimura
Esophageal cancer (EC) is the eleventh most commonly diagnosed cancer, and its prognosis remains poor. Several challenges remain for improving the clinical outcomes of EC, and improving technologies for early detection, diversifying treatment options, and advancing personalized treatment are essential. Alterations in the intestinal and esophageal microbiota are associated with the pathogenesis and progression of EC; for instance, Fusobacterium nucleatum is important in the pathogenesis and progression of esophageal squamous cell carcinoma. Therefore, a novel diagnostic biomarker may be identified using the intestinal microbiota. Furthermore, targeting the intestinal and esophageal microbiota may help in the early detection of EC, use of a novel prognostic biomarker, and even the detection of a therapeutic target, resulting in a more individualized therapeutic approach for EC. In this review, we summarize the clinical research focused on the intestinal and esophageal microbiota in EC development and its treatment, and discuss the challenges in the clinical application of intestinal and esophageal microbiota.

1 December 2019 in Transplantation Proceedings
Verified
Journal Article
Closed access
SFShun Fujiwara
Shun Fujiwara
NHNorimichi Hattori
Norimichi Hattori
TMTomoharu Matsui
Tomoharu Matsui
ANAyaka Nakata
Ayaka Nakata
YSYohei Sasaki
Yohei Sasaki
TNTsuyoshi Nakamaki
Tsuyoshi Nakamaki